Clinical trials: Genital Neoplasm
Neoplasms, Prostate
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
- Trial name
- NCT00363311
- Testing
- Dutasteride
- Where
- 82 sites in United States, Canada
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe…
- Trial name
- NCT07593092
- Testing
- XmAb541, XmAb808
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- Xencor, Inc.
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or…
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Trial name
- NCT01379534
- Testing
- TKI258
- Where
- 45 sites in United States, Brazil and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Multiple Myeloma
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment.
- Conditions
- Prostatic Neoplasms, Multiple Myeloma, Bladder Neoplasms, Lymphoma
- Trial name
- NCT00050687
- Testing
- Gallium maltolate
- Where
- 5 sites in United States
- Sponsor
- Titan Pharmaceuticals
Prostate Cancer
Phase 1 of EC1169 In Patients With Recurrent MCRPC
The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and…
- Trial name
- NCT02202447
- Testing
- EC1169, EC0652
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Endocyte
Prostate Cancer
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
This is a study in male patients with advanced prostate cancer who are eligible for androgen ablation therapy. The study duration will be up to 26 weeks. Eligibility will be assessed during a screening period of up to 28 days.
- Trial name
- KATANA E3M (NCT06795178)
- Testing
- FP-014
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor
- Trial name
- NCT05787535
- Testing
- Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell
- Where
- China
- Volunteers
- 17 people
- Sponsor
- HRYZ Biotech Co.
Cervical Intraepithelial Neoplasia
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
- Trial name
- NCT02596243
- Testing
- GX-188E
- Where
- 16 sites in Estonia, South Korea and 1 more
- Volunteers
- 134 people
- Sponsor
- Genexine, Inc.
Ovarian Cancer
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
The purpose of this study is to evaluate the efficacy, limited pharmacokinetics (PK), and safety of 1,000 mg of Panzem® NCD administered orally four times a day to patients with recurrent or resistant epithelial ovarian cancer.
- Trial name
- NCT00400348
- Testing
- Panzem Nanocrystal Colloidal Dispersion (NCD)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- CASI pharmaceuticals, Inc.
Ovarian Neoplasms, Peritoneal Neoplasms
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01932125
- Testing
- Bevacizumab
- Where
- 13 sites in India
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Ovarian Neoplasms, Fallopian Tube Neoplasms
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
The presence of single nucleotide polymorphisms (SNPs) in genes involved in platinum and taxane metabolism and detoxification have been correlated to increased risk of severe adverse events (AEs) when patients receive these…
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT02478476
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- OvaGene Oncology, Inc.
Human Papillomavirus (HPV) Infection
GARDASIL Reexamination Study (V501-059)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting…
- Trial name
- NCT01062074
- Volunteers
- 3,605 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Prostatic Neoplasms
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
This study was supposed to have assessed the safety and preliminary antitumor activity of CFG920, a new CYP17 inhibitor in castration resistant prostate cancer patients who are abiraterone naive or abiraterone resistant.
- Trial name
- NCT01647789
- Testing
- CFG920
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
HPV Infection, Lesion Cervix
Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.
Observational clinical study, national, multicentric, prospective, non-comparative, with medical device, under application consistent with CE marking, for the evaluation of Papilocare® effectivness in the normalization of cervix…
- Trial name
- PAPILOBS (NCT04199260)
- Testing
- papilocare vaginal gel
- Where
- 9 sites in Spain
- Volunteers
- 263 people
- Sponsor
- Procare Health Iberia S.L.
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
The primary objective of this study is to demonstrate the superior efficacy versus placebo of BG2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in…
- Trial name
- NCT05620355
- Testing
- BG2109, Add-back therapy
- Where
- 29 sites in China
- Volunteers
- 312 people
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.